Table 1 |
||||
| Demographic and clinical baseline characteristics of as-treated patients | ||||
| Characteristics | Probiotic n = 5 | Synbiotic n = 5 | Prebiotic n = 5 | Placebo n = 5 |
| Age, Mean ± SD | 28 ± 6 | 26 ± 7 | 27 ± 6 | 30 ± 8 |
| Gender | ||||
| Male | 4 | 5 | 4 | 5 |
| Female | 1 | 0 | 1 | 0 |
| Race (%) | ||||
| Hispanic | 5 (100) | 5 (100) | 5 (100) | 5 (100) |
| Body mass index (kg/m2) Mean ± SD | 24 ± 2 | 23 ± 6 | 25 ± 6 | 24 ± 6 |
| Clinical stage (%) | Stage A: 15 | Stage A: 14 | Stage A: 10 | Stage A: 18 |
| Stage B: 85 | Stage B: 86 | Stage B: 90 | Stage B: 82 | |
| HIV RNA level (copies/mL), median | 68100 | 56881 | 40800 | 54460 |
| CD4 cell count (cells/mm3), mean | 754 | 620 | 533 | 542 |
| Cholesterol (mg/dL) Mean ± SD | 137 ± 16 | 161 ± 32 | 179 ± 53 | 148 ± 13 |
| Triglycerides (mg/dL) Mean ± SD | 88 ± 27 | 105 ± 27 | 149 ± 65 | 118 ± 79 |
| IBS-QoL scale score | 34 | 36 | 35 | 34 |
González-Hernández et al. Nutrition Journal 2012 11:90 doi:10.1186/1475-2891-11-90
